Figure 3. Peripheral T-cell modulation in patients who received davoceticept monotherapy (NEON-1). Flow cytometric analyses of Ki67+CD4+ (A, B) and CD8+ (C, D) during treatment with davoceticept monotherapy Q1W (A, C) or Q3W (B, D). ***p=0.0005, **p=0.0017, *p=0.0313, not significant (ns). Error bars indicate stable disease where applicable. Q1W, once weekly; Q3W, once every 3 weeks.